Synonyms: Éculizumab; Eculizumabum; h5G1.1. Immunoglobulin, anti-(human complement C5 5G1.1 heavy chain), disulfide with human-mouse monoclonal 5G1.1 light chain, dimer.
Cyrillic synonym: Экулизумаб.

💊 Chemical information

CAS — 219685-50-4.
ATC — L04AA25.
ATC Vet — QL04AA25.

💊 Profile

Eculizumab is a recombinant humanised monoclonal antibody that acts as a complement blocker by inhibiting terminal complement activation at the C5 protein. It is used to reduce haemolysis in patients with paroxysmal nocturnal haemoglobinuria, a severe and disabling form of haemolytic anaemia. Eculizumab is given by intravenous infusion over 25 to 45 minutes in a dose of 600 mg every 7 days for the first 4 weeks, followed by 900 mg 7 days later, and then 900 mg every 14 days thereafter. The infusion should be diluted to 5 mg/mL in sodium chloride 0.45% or 0.9%, glucose 5%, or Ringer’s injection. The infusion rate may be decreased in the event of infusion reactions but the total infusion time should not exceed 2 hours; the infusion may be stopped in severe reactions. Patients should be monitored for at least one hour after the infusion for signs of infusion reactions. Patients who stop treatment altogether are at increased risk for serious haemolysis and should be monitored for 8 weeks. Use of eculizumab increases susceptibility to meningococcal infections and patients who are not up to date with their meningococcal vaccinations should be vaccinated at least 2 weeks before receiving the first dose of eculizumab and receive booster vaccinations according to current guidelines. Patients should be monitored during treatment for early signs of meningococcal infections and treated as required. Susceptibility to other infections may also increase and eculizumab should be used with caution in patients with systemic infection. Other adverse effects that have been reported with eculizumab include headache, nasopharyngitis, back pain, and nausea.
1. Hillmen P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233–43
2. Hillmen P, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110: 4123–8
3. Schubert J, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008; 142: 263–72
4. Charneski L, Patel PN. Eculizumab in paroxysmal nocturnal haemoglobinuria. Drugs 2008; 68: 1341–6.

💊 Preparations

Proprietary Preparations

Cz.: Soliris; Fr.: Soliris; Port.: Soliris; UK: Soliris; USA: Soliris.
Published May 08, 2019.